Lanthanides are valuable nonrenewable resources and widely used in a variety of industries. Detection and identification of lanthanide ions are in high demand but challenging because of the similarity among lanthanide ions. In the present work, a fluorescent sensor array of three cationic bispyrene derivatives mixed with anionic surfactant assemblies was developed. The sensor array exhibits cross-reactive responses to lanthanide ions when tested in aqueous solution. The combination of fluorescence variations at both monomer and excimer emission of each of the bispyrene sensor elements provides a six-signal recognition pattern for lanthanide ions. Principle component analysis illustrates that the sensor array could at least identify 6 of the 14 similar lanthanide ions including La(3+), Pr(3+), Nd(3+), Eu(3+), Ho(3+), and Er(3+). UV-vis absorption measurements rule out the possibility of binding lanthanides with fluorophores. Fluorescence titration experiments in both cationic and neutral surfactant aqueous solutions reveal that the three fluorophores show slight fluorescence responses to the lanthanide ions, indicating that electrostatic attraction between lanthanide ions and anionic surfactant plays an important role in the sensing behavior of the sensor array. Control experiments with divalent metal ions find no cross-reactive responses, suggesting that the stronger electrostatic interaction with trivalent lanthanide ions is responsible for the multiple fluorescence responses.
Interleukin 17A (IL-17A) exerts pleiotropic effects on periodontitis, partially through enhancement of alveolar bone loss. Osteoclasts are the main culprits that absorb alveolar bone. However, studies describing the correlation between IL-17A and osteoclasts are not conclusive. Previously, autophagy was revealed to be involved in osteoclast differentiation and bone resorption. However, the role of autophagy in IL-17A-mediated osteoclast formation is yet to be clarified. In the present study, bone marrow macrophages (BMMs) were treated with or without IL-17A. 3-Methyladenine (3-MA) was applied to inhibit autophagy. Osteoclast formation was detected by tartrate-resistant acid phosphatase (TRAP) staining, immunofluorescence, and scanning electron microscope. The effects of IL-17A on osteoclast-specific genes and autophagy-related genes during osteoclast differentiation were examined by real-time quantitative polymerase chain reaction and western blot analysis. Autophagosomes were observed by transmission electron microscope. Hematoxylin and eosin (H&E), and TRAP staining was adopted to assess alveolar bone destruction and the number of osteoclasts, respectively in a rat periodontitis model. Consequently, IL-17A stimulated osteoclast differentiation and bone resorption of BMMs accompanied by an increase in the mRNA expression of osteoclast-specific genes. Furthermore, IL-17A increased the levels of autophagy-related genes and proteins, and inhibition of autophagy with 3-MA attenuated the IL-17A-mediated osteoclastogenesis. In addition, there was an increase in the number of osteoclasts and alveolar bone resorption with IL-17A treatment in the periodontitis rat model. Collectively, these findings indicated that IL-17A facilitated osteoclast differentiation and bone resorption in vitro and in vivo , which may contribute to the understanding of the molecular basis of IL-17A in alveolar bone destruction and provide insight on the clinical therapeutic targets for periodontitis.
Biodegradable ceramic (composite) scaffolds have inspired worldwide efforts in bone regenerative medicine. However, balancing the biodegradation with the bone’s natural healing time scale remains difficult; in particularl, there is a lack of strategy to control component distribution and bioactive ion release favorable for stimulating alveolar bone tissue ingrowth in situ within an expected time window. Here we aimed to develop the robocasting core–shell bioceramic scaffolds and investigate their physicochemical properties and osteostimulative capability in beagle alveolar bone defect model. The β-tircalcium phosphate (TCP) and 5% Mg-doped calcium silicate (CSi-Mg5) were used to fabricate the core–shell-typed TCP@TCP, CSi-Mg5@CSi-Mg5 and TCP@CSi-Mg5 porous scaffolds. Both in vitro and in vivo studies show that the CSi-Mg5 shell readily contributed to the initial mechanical strength and early-stage osteogenic activity of the TCP@CSi-Mg5 scaffolds, including tunable ion release, enhanced biodegradation, and outstanding osteogenesis capacity in comparison with the CSi-Mg5@CSi-Mg5 scaffolds and clinically available Bio-Oss granules in alveolar bone defects. Therefore, the presented core–shell robocasting of bioceramic technology and porous scaffold biomaterials enables an accurate preparation of highly bioactive and biodegradable scaffolds with a large freedom of design, and thereby may be beneficial for fabricating osteostimulation-tuned porous scaffolds for the challengeable alveolar bone defect reconstruction medicine.
Background Leukoaraiosis (LA) severity is associated with poor outcome after mechanical thrombectomy (MT) for acute ischemic stroke (AIS) caused by large vessel occlusion. This meta-analysis aimed to assess the association of LA severity with AIS-related risk factors and outcomes of MT. Methods PubMed, Web of Science, EMBASE, and Cochrane Collaboration Database was searched for studies on MT for AIS with LA. We conducted a random-effects meta-analysis for the prevalence of stroke risk factors and the MT outcome in the absent to moderate LA and severe LA groups. Results We included seven cohort studies involving 1294 participants (1019 with absent to moderate LA and 275 with severe LA). The absent to moderate LA group had a significantly lower prevalence of coronary artery disease (odds ratio [OR] 0.43; 95% CI 0.29-0.66), atrial fibrillation (OR, 0.26; 95% CI 0.17-0.38), hypertension (OR, 0.39; 95% CI 0.24-0.61), and ischemic stroke (OR, 0.27; 95% CI 0.15-0.50) than the severe LA group. There were no significant between-group differences in symptom onset to recanalization time (364.4 versus 356.2 min, mean difference 19.4; 95% CI − 28.3 to 67.2), final recanalization rate (modified thrombolysis in cerebral infarction score of 2b/3; OR, 0.87; 95% CI 0.55-1.38), and symptomatic intracranial hemorrhage (OR, 0.62; 95% CI 0.34-1.11). The absent to moderate LA group had a higher good functional outcome (modified Rankin Scale score of 0-2 at 90 days; OR, 4.55; 95% CI 3.20-6.47) and a lower mortality rate (179/1019 vs 108/275; OR, 0.28; 95% CI 0.20-0.39). Conclusion There are unique differences in the characteristics of risk factors and clinical outcomes of ischemic stroke across patients with LA of different severity. Patients with severe LA are more likely to be associated with risk factors for cerebrovascular disease and have a poor post-MT outcome.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.